IL160597A0 - Cellular immunity test with peptides fixed on a solid support - Google Patents

Cellular immunity test with peptides fixed on a solid support

Info

Publication number
IL160597A0
IL160597A0 IL16059702A IL16059702A IL160597A0 IL 160597 A0 IL160597 A0 IL 160597A0 IL 16059702 A IL16059702 A IL 16059702A IL 16059702 A IL16059702 A IL 16059702A IL 160597 A0 IL160597 A0 IL 160597A0
Authority
IL
Israel
Prior art keywords
solid support
cellular immunity
immunity test
fixed
peptides fixed
Prior art date
Application number
IL16059702A
Other languages
English (en)
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of IL160597A0 publication Critical patent/IL160597A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL16059702A 2001-08-27 2002-08-27 Cellular immunity test with peptides fixed on a solid support IL160597A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111136A FR2828934B1 (fr) 2001-08-27 2001-08-27 Test de l'immunite cellulaire par des peptides fixes sur support solide
PCT/FR2002/002937 WO2003019195A2 (fr) 2001-08-27 2002-08-27 Test de l'immunite cellulaire par des peptides fixes sur support solide

Publications (1)

Publication Number Publication Date
IL160597A0 true IL160597A0 (en) 2004-07-25

Family

ID=8866750

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16059702A IL160597A0 (en) 2001-08-27 2002-08-27 Cellular immunity test with peptides fixed on a solid support

Country Status (11)

Country Link
US (2) US20060121537A1 (de)
EP (2) EP2037276A3 (de)
JP (1) JP4550414B2 (de)
AT (1) ATE414279T1 (de)
AU (1) AU2002341057A1 (de)
CA (1) CA2458986A1 (de)
DE (1) DE60229854D1 (de)
ES (1) ES2316620T3 (de)
FR (1) FR2828934B1 (de)
IL (1) IL160597A0 (de)
WO (1) WO2003019195A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29858A (id) * 1998-11-04 2001-10-18 Isis Innovation Uji diagnostik tuberkulosis
PL202927B1 (pl) * 2003-07-20 2009-08-31 Carr Daniel R Peptyd i kompozycja farmaceutyczna oraz ich zastosowania medyczne
BRPI0519399A2 (pt) * 2004-12-23 2009-01-20 Novo Nordisk As material de suporte sàlido e mÉtodo para isolamento de anticorpos ou derivados destes
CN101124238A (zh) * 2004-12-23 2008-02-13 诺和诺德公司 结合抗体的亲和性配体
WO2009115971A1 (en) * 2008-03-21 2009-09-24 Koninklijke Philips Electronics N.V. Method for communicating and radio station therefor
EP2258135B1 (de) * 2008-03-21 2012-09-26 Koninklijke Philips Electronics N.V. Verfahren und mobilstation zur aufwärtsstrecke betriebsmittelanforderung
RU2464571C1 (ru) * 2011-06-17 2012-10-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения специфического клеточного иммунного ответа к антигенам вируса кори и краснухи
US20220187279A1 (en) * 2020-12-14 2022-06-16 Immunitybio, Inc. Rapid t-cell assay for sars-cov-2

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5980899A (en) * 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
US6004763A (en) * 1992-09-11 1999-12-21 Institut Pasteur Antigen-carrying microparticles and their use in the induction of humoral or cellular responses
US5747265A (en) * 1992-10-30 1998-05-05 T Cell Diagnostics, Inc. Method for measuring the amount of a cell-associated molecule
US5595881A (en) * 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
AU740222C (en) * 1996-03-20 2002-10-10 Genzyme Corporation A method for identifying cytotoxic T-cell epitopes
WO1998023690A1 (en) * 1996-11-27 1998-06-04 Eastman Chemical Company Method for preparing light-absorbing polymeric compositions
WO1999037313A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Immune effector cell hybrids
DE19925235A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie

Also Published As

Publication number Publication date
JP2005501257A (ja) 2005-01-13
WO2003019195A3 (fr) 2004-01-22
DE60229854D1 (de) 2008-12-24
EP1421387B1 (de) 2008-11-12
JP4550414B2 (ja) 2010-09-22
EP2037276A2 (de) 2009-03-18
US20060121537A1 (en) 2006-06-08
EP2037276A3 (de) 2009-06-10
FR2828934B1 (fr) 2004-08-13
FR2828934A1 (fr) 2003-02-28
CA2458986A1 (fr) 2003-03-06
US20080213818A1 (en) 2008-09-04
WO2003019195A2 (fr) 2003-03-06
ES2316620T3 (es) 2009-04-16
ATE414279T1 (de) 2008-11-15
EP1421387A2 (de) 2004-05-26
AU2002341057A1 (en) 2003-03-10

Similar Documents

Publication Publication Date Title
NZ514887A (en) IBD-associated microbial antigens and methods of using same
AU2003253784A1 (en) Peptides from the e2, e6 and e7 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other cancers
DK1210430T3 (da) MUC-1-afledte peptider
DK0757717T3 (da) Papillomavirusvacciner
EP1795592A3 (de) Antikörper gegen im Blut vorhandene sekretierte N-terminale Peptide von GPC3 oder C-terminale Peptide von GPC3
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
IL160597A0 (en) Cellular immunity test with peptides fixed on a solid support
GB0215710D0 (en) Diagnostic method
AU2002223044A1 (en) Kit and method for detecting the esm-1 protein
IL145689A0 (en) Methods
ZA976196B (en) Peptide reagent for the detection of human cytomegalovirus (cmv)
DE60025704D1 (de) Das goodpasture-antigen bindende protein
AU2001276916A1 (en) Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
AU8542701A (en) Stress proteins and peptides and methods of use thereof
IT1271486B (it) Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
WO2003025134A3 (en) mcFP ENCODING NUCLEIC ACIDS, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE THEREOF
AU2002365084A1 (en) Method and reagent for the detection of proteins and peptides
AU2002338856A1 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
WO2002048184A3 (fr) Peptide de la glycoproteine b de l'herpesvirus humain 7 utilisable notamment dans un test serologique elisa
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
GB0004042D0 (en) Assay
WO2000017658A3 (en) Diagnosis of myocardial disease or stroke using factor ix activation peptide
GB9928491D0 (en) Detection of proteins, peptides and polypeptides
GB0111525D0 (en) Characterization of the prune gene, its encoding pbi protein and methods for s creening, diagnosing, prognosis and therapeutics of said condition